1. bookTom 49 (2015): Zeszyt 2 (June 2015)
Informacje o czasopiśmie
Pierwsze wydanie
30 Apr 2007
Częstotliwość wydawania
4 razy w roku
Open Access

Feasibility and safety of electrochemotherapy (ECT) in the pancreas: a pre-clinical investigation

Data publikacji: 25 Mar 2015
Tom & Zeszyt: Tom 49 (2015) - Zeszyt 2 (June 2015)
Zakres stron: 147 - 154
Otrzymano: 27 Dec 2014
Przyjęty: 12 Feb 2015
Informacje o czasopiśmie
Pierwsze wydanie
30 Apr 2007
Częstotliwość wydawania
4 razy w roku

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765-81.10.1016/j.ejca.2009.12.014Search in Google Scholar

2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.10.3322/caac.20107Search in Google Scholar

3. Krejs GJ. Pancreatic cancer: epidemiology and risk factors. Dig Dis 2010; 28: 355-8.10.1159/000319414Search in Google Scholar

4. Neoptolemos IP, Stocken DD, Friess H, Bassi C, M.D., Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. NEJM 2004; 350: 1200-10.10.1056/NEJMoa032295Search in Google Scholar

5. Gastrointestinal Tumour Study Group. Radiation therapy combined with adriamycin or 5-Fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Cancer 1985; 56: 2563-8.10.1002/1097-0142(19851201)56:11<2563::AID-CNCR2820561104>3.0.CO;2-0Search in Google Scholar

6. Klaassen DJ, MacIntyre JM, Catton GE, Engstrom PF, Moertel CG. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study. J Clin Oncol 1985; 3: 373-8.10.1200/JCO.1985.3.3.373Search in Google Scholar

7. Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouché O, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 2008; 19: 1592-9.10.1093/annonc/mdn281Search in Google Scholar

8. Loehrer PJ Sr, Feng Y, Cardenes H, Wagner L, Brell JM, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: An eastern cooperative oncology group trial. J Clin Oncol 2011; 29: 4105-12.10.1200/JCO.2011.34.8904Search in Google Scholar

9. Conroy T, Desseigne F, Ychou M., Bouché O, Guimbaud R, Bécouarn Y, et al. For the Groupe Tumeurs Digestives of Unicancer and the PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-25.10.1056/NEJMoa1011923Search in Google Scholar

10. Gillen S, Schuster T, Meyer zum Büschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: A systematic review and meta-analysis of response and resection percentages. PLoS Med 2010; 7(4): e1000267 2010.10.1371/journal.pmed.1000267Search in Google Scholar

11. Huguet F, André T, Hammel P, Artru P, Balosso J, Selle F, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR Phase II and III studies. J Clin Oncol 2007; 25: 226-331.10.1200/JCO.2006.07.566317235048Search in Google Scholar

12. Krishnan S, Rana V, Janjan NA, Varadhachary GR, Abbruzzese JL, Das P, et al: Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer 2007; 110: 47-55.10.1002/cncr.2273517538975Search in Google Scholar

13. Katrina F. Chu and Damian E. Dupuy. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nature Rev 2014; 14: 199-208.Search in Google Scholar

14. Giardino A, Girelli R, Lusenti A, Auriemma A, Bassi C, Cantore M, et al. Triple approach strategy for patients with locally advanced pancreatic carcinoma. HPB (Oxford) 2013; 15: 623-7.10.1111/hpb.12027373158423458679Search in Google Scholar

15. Girelli R, Gobbo S, Malleo G, Regi P, Salvia R, Frigerio I, et al. Results of 100 pancreatic radiofrequency ablations in the context of a multimodal strategy for stage III ductal adenocarcinoma. Langenbecks Arch Surg 2013; 398: 63-9.10.1007/s00423-012-1011-z23053459Search in Google Scholar

16. Cantore M, Frigerio I, Giardino A, Girelli R, Mambrini A, Orlandi M, et al: Combined modality treatment for patients with locally advanced pancreatic adenocarcinoma. Brit J Surg 2012; 99: 1083-8.10.1002/bjs.878922648697Search in Google Scholar

17. Girelli R, Frigerio I, Salvia R, Barbi E, Tinazzi Martini P, et al. Feasibility and safety of radiofrequency ablation for locally advanced pancreatic cancer. Brit J Surg 2010; 97: 220-5.10.1002/bjs.680020069610Search in Google Scholar

18. Shi X, L iu S, Kleeff J, Friess H, Büchler MW. Acquired resistance of pancreatic cancer cells towards 5-Fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology 2002; 62: 354-62.10.1159/00006506812138244Search in Google Scholar

19. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 2009; 69: 5820-8.10.1158/0008-5472.CAN-08-2819437869019584296Search in Google Scholar

20. Tamburrin o A, Piro G, Carbone C, Tortora G, Melisi D. Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy. Front Pharmacol 2013; 4: 56.10.3389/fphar.2013.00056363940723641216Search in Google Scholar

21. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1: 313-23.10.1016/j.stem.2007.06.00218371365Search in Google Scholar

22. Li C, Hei dt DG, Dalerba P, Burant CF, Zhang L, Adsay V, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-7.10.1158/0008-5472.CAN-06-2030Search in Google Scholar

23. Thiery JP , Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-90.10.1016/j.cell.2009.11.007Search in Google Scholar

24. Bria E, M ilella M, Gelibter A, Cuppone F, Pino MS, Ruggeri EM, et al. Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trials. Cancer 2007; 110: 525-33.10.1002/cncr.22809Search in Google Scholar

25. Olson P, Hanahan D. Cancer. Breaching the cancer fortress. Science 2009; 324: 1400-1.10.1126/science.1175940Search in Google Scholar

26. Neumann E , Schaefer-Ridder M, Wang Y, Hofschneider PH. Gene transfer into mouse lyoma cells by electroporation in high electric field. EMBO J 1982; 1: 841-5.10.1002/j.1460-2075.1982.tb01257.xSearch in Google Scholar

27. Neumann E , Kakorin S, Toesing K. Fundamentals of electroporative delivery of drugs and genes. Bioelectrochem Bioenerg 1999; 48: 3-16.10.1016/S0302-4598(99)00008-2Search in Google Scholar

28. Orlowski S, Mir LM. Cell electropermeabilization: a new tool for biochemical and pharmacological studies. Biochim Biophys Acta 1993; 1154: 51-63.10.1016/0304-4157(93)90016-HSearch in Google Scholar

29. Gehl J. E lectroporation: theory and methods, perspectives for drug delivery, gene therapy and research. Acta Physiol Scand 2003; 177: 437-47.10.1046/j.1365-201X.2003.01093.xSearch in Google Scholar

30. Mir LM, O rlowski S, Belehradek M and Paoletti C. Electrochemotherapy: potentiation of antitumor effect of bleomycin by local electric pulses. Eur J Cancer 1991; 1: 68-72.10.1016/0277-5379(91)90064-KSearch in Google Scholar

31. Belehrade k M, Domenge C, Luboinski B, Orlowski S, Belehradek Jr. J, Mir LM. Electrochemotherapy, a new antitumor treatment - first clinical phase I‒II trial. Cancer 1993; 72: 3694-700.10.1002/1097-0142(19931215)72:12<3694::AID-CNCR2820721222>3.0.CO;2-2Search in Google Scholar

32. Marty M, S ersa G, Garbay JR, Gehl J, Collins CG, Snoj M, et al: Electrochemotherapy - an easy, highly effective and safe treatment of cutaneous and subcutaneous metastases. Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. Eur J Cancer 2006; S4: 3-13.10.1016/j.ejcsup.2006.08.002Search in Google Scholar

33. Sersa G, Sta buc B, Cemazar M, Jancar B, Miklavcic D, Rudolf Z. Electrochemotherapy with CDDP: potentiation of local CDDP antitumor effectiveness by application of electric pulses in cancer patients. Eur J Cancer 1998; 34: 1213-8.10.1016/S0959-8049(98)00025-2Search in Google Scholar

34. Sersa G, Sta buc B, Cemazar M, Miklavcic D, Rudolf Z. Electrochemotherapy with cisplatin: clinical experience in malignant melanoma patients. Clin Cancer Res 2000; 6: 863-7.Search in Google Scholar

35. Matthiessen LW, Johannesen HH, Hendel HW, Moss T, Kamby C, Gehl J. Electrochemotherapy for large cutaneous recurrence of breast cancer: A phase II clinical trial. Acta Oncol 2012; 51: 713-21.10.3109/0284186X.2012.68552422731832Search in Google Scholar

36. Mevio N, Ber tino G, Occhini A, Scelsi D, Tagliabue M, Mura F, et al. Electrochemotherapy for the treatment of recurrent head and neck cancers: preliminary results. Tumori 2012; 98: 308-13.10.1177/030089161209800305Search in Google Scholar

37. Curatolo P, Quaglino P, Marenco F, Mancini M, Nardò T, Mortera C, et al. Electrochemotherapy in the treatment of kaposi sarcoma cutaneous lesions: A two-center prospective phase II trial. Ann Surg Oncol 2012; 1: 192-8.10.1245/s10434-011-1860-721822561Search in Google Scholar

38. Campana LG, Va lpione S, Mocellin S, Sundararajan R, Granziera E, Sartore L, et al. Electrochemotherapy for disseminated superficial metastases from malignant melanoma. Br J Surg 2012; 99: 821-30.10.1002/bjs.874922508342Search in Google Scholar

39. Fini M, Salama nna F, Parrilli A, Martini L, Cadossi M, Maglio M, et al. Electrochemotherapy is effective in the treatment of rat bone metastases. Clin Exp Met 2013; 30: 1033-45.10.1007/s10585-013-9601-x23832763Search in Google Scholar

40. Edhemovic I, G adzijev EM, Brecelj E, Miklavcic D, Kos B, Zupanic A, et al. Electrochemotherapy: a new technological approach in treatment of metastases in the liver. Technol Cancer Res Treat 2011; 10: 475-85.10.7785/tcrt.2012.500224452741421895032Search in Google Scholar

41. Edhemovic I, B recelj E, Gasljevic G, Marolt Music M, Gorjup V, Mali B et al. Intraoperative electrochemotherapy of colorectal liver metastases. J Surg Oncol 2014; 110: 320-7.10.1002/jso.2362524782355Search in Google Scholar

42. Heller R, Ja roszeski M, Perrot R, Messina J and Gilbert R: Effective treatment of B16 melanoma by direct delivery of bleomycin using electrochemotherapy. Melanoma Res 1997; 7: 10-8.10.1097/00008390-199702000-000039067960Search in Google Scholar

43. Sersa G., Cema zar M, Miklavcic D, Mir LM. Electrochemotherapy: variable anti-tumor effect on different tumor models. Bioelectrochem Bioenerg 1994; 35: 23-7.10.1016/0302-4598(94)87006-3Search in Google Scholar

44. Pendez S, Jaro szeski MJ, Gilbert R Hyacinthe M, Dang V, Hickey J, et al. Direct delivery of chemotherapeutic agents for the treatment of hepatoma and sarcoma in rat models. Radiol Oncol 1998; 21: 53-64.Search in Google Scholar

45. Sersa G, Novak ovic S, Miklavcic D: Potentiation of bleomycin antitumor effectiveness by electrochemotherapy. Cancer Lett 1993; 69: 81-4.10.1016/0304-3835(93)90159-7Search in Google Scholar

46. Nanda GS, Sun FX, Hofmann GA, Hofmann RM, Dev SB. Electroporation enhances therapeutic efficacy of anticancer drugs: treatment of human pancreatic tumor in animal model. Anticancer Res 1988; 18: 1361-6.Search in Google Scholar

47. Jaroszeski MJ, Gilbert RA, Heller R. In vivo antitumor effects of electrochemotherapy in a hepatoma model. Bioch Biophis Acta 1997; 1334: 15-8.10.1016/S0304-4165(96)00147-XSearch in Google Scholar

48. Ramirez LH, Or lowski S, An D, Gindoula G, Dzodic R, Ardouin P, et al. Electrochemotherapy on liver tumours in rabbit. Br. J Cancer 1998; 77: 2104-11.10.1038/bjc.1998.35421503839649121Search in Google Scholar

49. Jaroszeski MJ, Illingworth P, Pottinger C, Hyacinthe M, Miller R. Electrically mediated drug delivery for treating subcutaneous and orthotopic pancreatic adenocarcinoma in a hamster model. Anticancer Res 1999; 19: 989-94.Search in Google Scholar

50. Liu X, Tian X, Wang F, Ma Y, Kornmann M, Yang Y. BRG1 promotes chemoresistance of pancreatic cancer cells through crosstalking with Akt signalling. Eur J Cancer 2014; 50: 2251-62.10.1016/j.ejca.2014.05.01724953335Search in Google Scholar

51. Granata V, Fus co R, Piccirillo M. Palaia R, Lastoria A, Petrillo A, et al. Feasibility and safety of intraoperative electrochemotherapy in locally pancreatic tumor: A preliminary experience. Eur J Inflamm 2014; 12: 467-77.10.1177/1721727X1401200308Search in Google Scholar

52. Allegretti JP, Panje WR. Electroporation therapy for head and neck cancer including carotid artery involvement. Laryngoscope 2001; 111: 52-6.10.1097/00005537-200101000-0001011192900Search in Google Scholar

53. Bloom DC, Gold farb PM. The role of intratumour therapy with electroporation and bleomycin in the management of advanced squamous cell carcinoma of the head and neck. Eur J Surg Oncol 2005; 31: 1029-35.10.1016/j.ejso.2005.04.00716150565Search in Google Scholar

54. Miklavcic D, S ersa G, Brecelj E, Gehl J, Soden D, Bianchi G, Ruggieri P, Rossi CR, Campana LG, Jarm T. Electrochemotherapy: technological advancements for efficient electroporation-based treatment of internal tumors. Med Biol Eng Comput 2012; 50: 1213-25.10.1007/s11517-012-0991-8351469923179413Search in Google Scholar

55. Todorovic V, S ersa G, Flisar K, Cemazar M. Enhanced cytotoxicity of bleomycin and cisplatin after electroporation in murine colorectal carcinoma cells. Radiol Oncol 2009; 43: 264-73.10.2478/v10019-009-0037-5Search in Google Scholar

56. Cemazar M, Tam zali Y, Sersa G, Tozon N, Mir LM, Miklavcic D, et al. Electrochemotherapy in veterinary oncology. J Vet Inter Med 2008; 22: 826-31. 10.1111/j.1939-1676.2008.0117.x18537879Search in Google Scholar

Polecane artykuły z Trend MD

Zaplanuj zdalną konferencję ze Sciendo